A comparative study of a new drug MK 185 with clofibrate in the treatment of hyperlipidaemias.
D000081:Acetamides / Q000627:therapeutic use; D001796:Blood Protein Disorders / Q000097:blood / Q000188:drug therapy*; D001797:Blood Protein Electrophoresis; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D005227:Fatty Acids / Q000097:blood; D005461:Fluorine / Q000627:therapeutic use; D006016:Glycolates / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D010919:Placebos; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D000081:Acetamides; D005227:Fatty Acids; D006016:Glycolates; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010919:Placebos; D014280:Triglycerides; D014527:Uric Acid; D005461:Fluorine; D002784:Cholesterol; D002994:Clofibrate